BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, March 11, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
March 11, 2022
View Archived Issues
Discovery of novel orally active FXR agonist with improved potency
Read More
Researchers present a promising approach for efficient solid tumor cell killing
Read More
Discovery of novel antioxidant, antiedematogenic and antinociceptive compound
Read More
New York Blood Center patents new antiviral compounds
Read More
Hanmi Science divulges new EZH inhibitors
Read More
Medshine Discovery discloses new S1PR1 agonists
Read More
Betta Pharmaceuticals presents YAP1 or TAZ/TEAD interaction inhibitors
Read More
Sunshine Lake Pharma identifies new GTPase KRAS mutant inhibitors
Read More
Osmolytes induce kidney EMT
Read More
Small Pharma eyes clinic with DMT candidate SPL-028
Read More
Aligos advances early-stage programs
Read More
Viridian Therapeutics offers update on nonclinical pipeline
Read More
Researchers suggest IL-33R modulation for controlling lung inflammation and pulmonary fibrosis
Read More
STK-002 enters preclinical toxicology studies for autosomal dominant optic atrophy
Read More
Oncternal advances ONCT-808 toward IND filing and ONCT-534 into IND-enabling studies
Read More
AEterna Zentaris expands research agreement with JMU to support COVID-19 and Chlamydia vaccines
Read More
Morningside Ventures launches Adiso Therapeutics focused on inflammatory diseases
Read More
Poseida Therapeutics reports progress across nonclinical programs
Read More
Sensei advances preclinical pipeline based on TMAb and ImmunoPhage platforms
Read More
